ACRP-CP FINAL EXAM PREP 2026
ULTIMATE RISK-BASED MONITORING
(RBM) AND ICH E6(R3) CHEAT SHEET
(GRADED A MASTER GUIDE)
This premium study guide delivers an exhaustive, master-
level blueprint of Risk-Based Monitoring (RBM) and Quality-
by-Design (QbD) frameworks tailored specifically to the
latest clinical research regulations. It bridges foundational
ICH E6(R2) monitoring metrics directly with cutting-edge
ICH E6(R3) risk assessment matrices, ensuring complete
preparation for advanced industry certifications. Packed
with 200 sequentially formatted practice questions, verified
detailed answers, and high-yield rationales, this document
serves as an indispensable tool for achieving an elite grade
on your final examination.
Question 1
An investigator plans to implement an amendment to a protocol to eliminate
an immediate hazard to trial subjects without prior IRB/IEC approval.
According to ICH E6, this action is:
A. Permissible only if the sponsor grants verbal permission first.
B. Prohibited under all circumstances until full written approval is secured.
C. Permissible, but the implemented change must be submitted to the
,IRB/IEC as soon as possible.
D. Allowed only if a co-investigator signs off on the emergency waiver.
Answer: C
Rationale: ICH E6 states that an investigator may implement a
deviation from, or a change of, the protocol to eliminate an immediate
hazard to trial subjects without prior IRB/IEC approval. This must be
submitted as soon as possible to the IRB/IEC for review, the sponsor
for agreement, and the regulatory authorities if required.
Question 2
During an ongoing clinical trial, a sponsor decides to transition from paper
Case Report Forms (CRFs) to an Electronic Data Capture (EDC) system.
The EDC system must strictly conform to requirements for:
A. Direct daily backups onto local physical external drives at the site.
B. Validation, accuracy, reliability, and consistent performance.
C. Open-source availability so all site staff can modify the code base.
D. Eliminating the need for an investigator signature on data entries.
Answer: B
Rationale: When using electronic trial data management systems, the
sponsor must ensure and document that the electronic data
processing system conforms to established requirements for
validation, accuracy, reliability, and completeness.
Question 3
Which of the following elements is considered a regulatory criterion for an
event to be classified as a Serious Adverse Event (SAE)?
A. Any event requiring an over-the-counter medication change.
B. An event resulting in persistent or significant disability/incapacity.
C. A mild headache that causes the subject to miss one day of work.
D. Any protocol deviation involving an incorrect dose calculation.
Answer: B
,Rationale: An SAE is defined as any untoward medical occurrence
that at any dose results in death, is life-threatening, requires inpatient
hospitalisation or prolongation of existing hospitalisation, results in
persistent or significant disability/incapacity, or is a congenital
anomaly/birth defect.
Question 4
Who is explicitly required by ICH E6 guidelines to sign and date the written
Informed Consent Form (ICF)?
A. Only the subject and a designated family witness.
B. The investigator, the sponsor monitor, and the subject.
C. The person who conducted the informed consent interview and the
subject (or their legally acceptable representative).
D. The IRB/IEC chairperson and the site study coordinator.
Answer: C
Rationale: ICH guidelines mandate that the written informed consent
form should be signed and personally dated by the subject or by the
subject's legally acceptable representative, and by the person who
conducted the informed consent discussion.
Question 5
A clinical trial sponsor must retain essential documents and unused trial
investigational products (IP) until:
A. At least 1 year after the final site monitoring visit.
B. The site study coordinator completes the local archiving process.
C. The analyses of trial data are complete, or as required by regulatory
mandates (whichever is longer).
D. The IRB/IEC issues its final closeout invoice acknowledgment.
Answer: C
Rationale: Essential documents and IP records must be retained by
the sponsor for a minimum period specified by regulatory
requirements or until data analysis is complete, choosing whichever
timeframe provides the longer protection.
, Question 6
What is the core, primary foundational purpose of the Institutional Review
Board / Independent Ethics Committee (IRB/IEC)?
A. To guarantee the sponsor achieves statistical significance in trial
endpoints.
B. To protect the financial interests and liability limits of the research
institution.
C. To safeguard the rights, safety, and well-being of all trial subjects.
D. To accelerate the timeline for investigational product marketing
approvals.
Answer: C
Rationale: The primary responsibility of an IRB/IEC is to safeguard the
rights, safety, and well-being of all trial subjects. Special attention
should be paid to trials that may include vulnerable subjects.
Question 7
Which of the following best describes a "crossover" clinical trial design?
A. Subjects are assigned to parallel groups that never meet or share
treatments.
B. Each subject is randomized to a sequence of two or more treatments
and acts as their own control.
C. A design where data from an entirely separate historical trial is used as a
control group.
D. A trial where the investigator changes the protocol halfway through
enrollment.
Answer: B
Rationale: In a crossover design, subjects receive different treatments
sequentially over separate periods. Because each subject receives
both the active drug and/or comparator, they act as their own internal
control, reducing variability.
Question 8
ULTIMATE RISK-BASED MONITORING
(RBM) AND ICH E6(R3) CHEAT SHEET
(GRADED A MASTER GUIDE)
This premium study guide delivers an exhaustive, master-
level blueprint of Risk-Based Monitoring (RBM) and Quality-
by-Design (QbD) frameworks tailored specifically to the
latest clinical research regulations. It bridges foundational
ICH E6(R2) monitoring metrics directly with cutting-edge
ICH E6(R3) risk assessment matrices, ensuring complete
preparation for advanced industry certifications. Packed
with 200 sequentially formatted practice questions, verified
detailed answers, and high-yield rationales, this document
serves as an indispensable tool for achieving an elite grade
on your final examination.
Question 1
An investigator plans to implement an amendment to a protocol to eliminate
an immediate hazard to trial subjects without prior IRB/IEC approval.
According to ICH E6, this action is:
A. Permissible only if the sponsor grants verbal permission first.
B. Prohibited under all circumstances until full written approval is secured.
C. Permissible, but the implemented change must be submitted to the
,IRB/IEC as soon as possible.
D. Allowed only if a co-investigator signs off on the emergency waiver.
Answer: C
Rationale: ICH E6 states that an investigator may implement a
deviation from, or a change of, the protocol to eliminate an immediate
hazard to trial subjects without prior IRB/IEC approval. This must be
submitted as soon as possible to the IRB/IEC for review, the sponsor
for agreement, and the regulatory authorities if required.
Question 2
During an ongoing clinical trial, a sponsor decides to transition from paper
Case Report Forms (CRFs) to an Electronic Data Capture (EDC) system.
The EDC system must strictly conform to requirements for:
A. Direct daily backups onto local physical external drives at the site.
B. Validation, accuracy, reliability, and consistent performance.
C. Open-source availability so all site staff can modify the code base.
D. Eliminating the need for an investigator signature on data entries.
Answer: B
Rationale: When using electronic trial data management systems, the
sponsor must ensure and document that the electronic data
processing system conforms to established requirements for
validation, accuracy, reliability, and completeness.
Question 3
Which of the following elements is considered a regulatory criterion for an
event to be classified as a Serious Adverse Event (SAE)?
A. Any event requiring an over-the-counter medication change.
B. An event resulting in persistent or significant disability/incapacity.
C. A mild headache that causes the subject to miss one day of work.
D. Any protocol deviation involving an incorrect dose calculation.
Answer: B
,Rationale: An SAE is defined as any untoward medical occurrence
that at any dose results in death, is life-threatening, requires inpatient
hospitalisation or prolongation of existing hospitalisation, results in
persistent or significant disability/incapacity, or is a congenital
anomaly/birth defect.
Question 4
Who is explicitly required by ICH E6 guidelines to sign and date the written
Informed Consent Form (ICF)?
A. Only the subject and a designated family witness.
B. The investigator, the sponsor monitor, and the subject.
C. The person who conducted the informed consent interview and the
subject (or their legally acceptable representative).
D. The IRB/IEC chairperson and the site study coordinator.
Answer: C
Rationale: ICH guidelines mandate that the written informed consent
form should be signed and personally dated by the subject or by the
subject's legally acceptable representative, and by the person who
conducted the informed consent discussion.
Question 5
A clinical trial sponsor must retain essential documents and unused trial
investigational products (IP) until:
A. At least 1 year after the final site monitoring visit.
B. The site study coordinator completes the local archiving process.
C. The analyses of trial data are complete, or as required by regulatory
mandates (whichever is longer).
D. The IRB/IEC issues its final closeout invoice acknowledgment.
Answer: C
Rationale: Essential documents and IP records must be retained by
the sponsor for a minimum period specified by regulatory
requirements or until data analysis is complete, choosing whichever
timeframe provides the longer protection.
, Question 6
What is the core, primary foundational purpose of the Institutional Review
Board / Independent Ethics Committee (IRB/IEC)?
A. To guarantee the sponsor achieves statistical significance in trial
endpoints.
B. To protect the financial interests and liability limits of the research
institution.
C. To safeguard the rights, safety, and well-being of all trial subjects.
D. To accelerate the timeline for investigational product marketing
approvals.
Answer: C
Rationale: The primary responsibility of an IRB/IEC is to safeguard the
rights, safety, and well-being of all trial subjects. Special attention
should be paid to trials that may include vulnerable subjects.
Question 7
Which of the following best describes a "crossover" clinical trial design?
A. Subjects are assigned to parallel groups that never meet or share
treatments.
B. Each subject is randomized to a sequence of two or more treatments
and acts as their own control.
C. A design where data from an entirely separate historical trial is used as a
control group.
D. A trial where the investigator changes the protocol halfway through
enrollment.
Answer: B
Rationale: In a crossover design, subjects receive different treatments
sequentially over separate periods. Because each subject receives
both the active drug and/or comparator, they act as their own internal
control, reducing variability.
Question 8
